Edoxaban tosylate hydrate
| Title | Journal |
|---|---|
| Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa. | Clinical pharmacokinetics 20160101 |
| Overview of the new oral anticoagulants: opportunities and challenges. | Arteriosclerosis, thrombosis, and vascular biology 20150501 |
| The role of factor Xa inhibitors in venous thromboembolism treatment. | Vascular health and risk management 20150101 |
| Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery. | Thrombosis and haemostasis 20121101 |
| Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options. | Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing 20121001 |
| Oral direct factor Xa inhibitors. | Circulation research 20120928 |
| Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats. | Thrombosis research 20120901 |
| The promise of novel direct oral anticoagulants. | Best practice & research. Clinical haematology 20120901 |
| Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects. | Thrombosis and haemostasis 20120701 |
| Long-term benefits of preventing venous thromboembolic events. | Current medical research and opinion 20120601 |
| Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation. | Critical pathways in cardiology 20120601 |
| In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. | Thrombosis research 20120401 |
| Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation. | Circulation journal : official journal of the Japanese Circulation Society 20120101 |
| Comparison of antithrombotic efficacy between edoxaban, a direct factor Xa inhibitor, and fondaparinux, an indirect factor Xa inhibitor under low and high shear rates. | Thrombosis and haemostasis 20111201 |
| Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system. | Thrombosis and haemostasis 20111201 |
| [Current status and future of anti-Xa inhibitors]. | Rinsho shinkeigaku = Clinical neurology 20111101 |
| The new oral anticoagulants. | Clinical medicine (London, England) 20111001 |
| Edoxaban for the prevention of thromboembolic events after surgery. | Drugs of today (Barcelona, Spain : 1998) 20111001 |
| [Thromboembolic prophylaxis 2011: is warfarin on the wane?]. | Giornale italiano di cardiologia (2006) 20110901 |
| Edoxaban: a new oral direct factor xa inhibitor. | Drugs 20110820 |
| Edoxaban: pharmacological principles, preclinical and early-phase clinical testing. | Future cardiology 20110701 |
| [New anticoagulants in the prevention and treatment of venous thromboembolism]. | Orvosi hetilap 20110619 |
| Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux. | Thrombosis and haemostasis 20110601 |
| Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. | Thrombosis and haemostasis 20110301 |
| Factor Xa and thrombin as targets for new oral anticoagulants. | Thrombosis research 20110101 |
| Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. | Annual review of medicine 20110101 |
| Edoxaban tosylate. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20110101 |
| A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. | Journal of thrombosis and haemostasis : JTH 20101101 |
| Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults. | Thrombosis research 20101001 |
| Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). | American heart journal 20101001 |
| Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. | Thrombosis and haemostasis 20100901 |
| Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. | Thrombosis and haemostasis 20100901 |
| [Do orally active factor Xa (FXa) inhibitors have potential as innovative new anticoagulants? Future perspective from preclinical data]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20100801 |
| Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. | Journal of clinical pharmacology 20100701 |
| Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation. | Current opinion in cardiology 20100701 |
| New anticoagulants for atrial fibrillation. | Seminars in thrombosis and hemostasis 20090701 |
| DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. | Journal of thrombosis and haemostasis : JTH 20080901 |